Determinants of antibody response to severe acute respiratory syndrome coronavirus 2 mRNA vaccines in people with HIV.

Authors :: Chammartin F
Kusejko K
Pasin C
Trkola A
Briel M
Amico P
Stoekle MP
Eichenberger AL
Hasse B
Braun DL
Schuurmans MM
Müller TF
Tamm M
Mueller NJ
Rauch A
Koller MT
Günthard HF
Bucher HC
Speich B
Abela IA
Source :: AIDS (London, England) [AIDS] 2022 Aug 01; Vol. 36 (10), pp. 1465-1468. Date of Electronic Publication: 2022 Jul 09.
Publication Year :: 2022
Abstract: We identified determinants of SARS-CoV-2 mRNA vaccine antibody response in people with HIV (PWH). Antibody response was higher among PWH less than 60 years, with CD4+ cell count superior to 350 cells/μl and vaccinated with mRNA-1273 by Moderna compared with BNT162b2 by Pfizer-BioNTech. Preinfection with SARS-CoV-2 boosted the antibody response and smokers had an overall lower antibody response. Elderly PWH and those with low CD4+ cell count should be prioritized for booster vaccinations.<br /> (Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc.)

Subjects :: Aged
Antibodies, Viral
Antibody Formation
BNT162 Vaccine
COVID-19 Vaccines
Humans
RNA, Messenger
SARS-CoV-2
Vaccines, Synthetic
mRNA Vaccines
COVID-19 prevention & control
HIV Infections complications

Full Text Access

Tools